Impact of serotonin on tumour growth

References

• Seuwen K, Pouyssegur J. Serotonin as a growth factor. Biochem Pharmacol 1990; 39: 985–90
   PubMed Web of Science ®Google Scholar
• Kavanaugh W M, Williams L T, Ives H E, Coughlin S R. Serotonin-induced deoxyribonucleic acid synthesis in vascular smooth muscle cells involves a novel, pertussis toxin-sensitive pathway. Mol Endocrinol 1988; 2: 599–605
   PubMedGoogle Scholar
• Seuwen K, Magnaldo I, Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature 1988; 335: 254–6
   PubMed Web of Science ®Google Scholar
• Horai T, Nishihara H, Tateishi R, Matsuda M, Hattori S. Oat-cell carcinoma of the lung simultaneously producing ACTH and serotonin. J Clin Endocrinol Metab 1973; 37: 212–3
   PubMedGoogle Scholar
• Cattaneo M G, Codignola A, Vicentini L M, Clementi F, Sher E. Nicotine stimulates a serotoninergic autocrine loop in human small-cell lung carcinoma. Cancer Res 1993; 53: 5566–8
   PubMed Web of Science ®Google Scholar
• Cattaneo M G, Palazzi E, Bondiolotti G, Vicentini L M. 5-HTlD receptor type is involved in stimulation of cell proliferation by serotonin in human small cell lung carcinoma. Eur J Pharmacol Mol Pharmacol 1994; 268: 425–30
   PubMedGoogle Scholar
• Sheehan P FJ, Baker T, Tutton P JM, Barkla D H. Effects of histamine and 5-hydroxytryptamine on the growth rate of xenografted human bronchogenic carcinomas. Clin Exp Pharmacol Physiol 1996; 23: 465–71
   PubMedGoogle Scholar
• Hoosein N M, Bandyk M G, Nicolson G L, Logothesis C J, Chung L WK. Expression of neuroendocrine markers and extracellular matrix degradative enzymes in human prostate tumour cells (abstract). J Urol 1993; 149: 479A
   Google Scholar
• Abdul M, Anezinis P E, Logothetis C J, Hoosein N M. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994; 14: 1215–20
   PubMed Web of Science ®Google Scholar
• Ishizuka L, Beauchamp R D, Townsend J C, Greeley G H, Thompson J C. Receptor-mediated autocrine growth-stimu-latory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells. J Cell Physiol 1992; 150: 1–7
   PubMed Web of Science ®Google Scholar
• Pratesi G, Cervi S, Balsari A, Bondiolotti G, Vicentini L M. Effect of serotonin and nicotine on the growth of a human small cell lung cancer xenograft. Anticancer Res 1996; 16: 3615–20
   PubMed Web of Science ®Google Scholar
• Orvoine R H, Seidman J M. Induction of acute necrosis in Walker 256 tumours in rats. Cancer Res 1977; 37: 102–5
   PubMedGoogle Scholar
• Orvoine R H. Influence of various hexoses and vasoactive agents on osmotically induced oncolysis. Cancer Res 1981; 41: 5044–8
   PubMedGoogle Scholar
• Crile G J. The effects of heat and radiation on cancers implanted on the feet of mice. Cancer Res 1963; 23: 372–80
   PubMed Web of Science ®Google Scholar
• Manda T, Nishigaki F, Mori J, Shimomura K. Important role of serotonin in the antitumour effects of recombinant human tumour necrosis factor-alpha in mice. Cancer Res 1988; 48: 4250–5
   PubMed Web of Science ®Google Scholar
• Stiicker O, Vicaut E, Teisseire B. Specific response to 5-HT2 agonists by arterioles linked to Meth A turnours in mice. Am J Pbysiol 1992; 262: H704–9
   Google Scholar
• Burtin C, Scheinmann P, Salomon J C, Lespinats G, Canu P. Decrease in tumour growth by injection of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors. Br J Cancer 1982; 45: 54–61
   PubMed Web of Science ®Google Scholar
• Stúcker O, Vicaut E, Teisseire B. Hyper-responsiveness to 5-HT, agonists by tumour-feeding arterioles in mice: consequences for tumour growth. Int J Radiat Biol 1991; 60: 237–41
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumour angiogenesis. Adu Cancer Res 1985; 43: 175–203
   PubMed Web of Science ®Google Scholar
• Cater D B, Schoeniger E L, Watkinson D A. Effect of breathing high pressure oxygen upon tissue oxygen tension in rat and mouse tumours. Acta Radiol Tber Phys Biol 1963; 1: 233–52
   PubMed Web of Science ®Google Scholar
• Shrivastav S, Joines W T, Jirtle R L. Effect of S-hydroxytryptamine on tissue blood flow and microwave heating of rat tumours. Cancer Res 1985; 45: 3203–8
   PubMedGoogle Scholar
• Majno G, Shea S M, Leventhal M S. Endothelial contraction induced by histamine-type mediators. An electron microscopic study. J Cell Biol 1969; 42: 647–72
   PubMed Web of Science ®Google Scholar
• Laemmel E, Stücker O, Darmon P L, Vicaut E. Characterization of the specific response to serotonin of mouse tumour-feeding arterioles. Int J Radiat Biol 1998; 74: 379–86
   PubMedGoogle Scholar
• Lübbe A S, Huhnt W. Microvessel diameters of human colon adenocarcinoma during acute treatment with serotonin. Int J Microcirc 1994; 14: 218–25
   PubMedGoogle Scholar
• Stiicker O, Laemmel E, Teisseire B, Vicaut E. Specific response of mouse tumour-feeding arterioles to stimulation by 5-HT1 agonists. Int J Radiat Oncol Biol Phys 1997; 37: 1125–31
   PubMedGoogle Scholar
• Sikorski B W, James G M, Glance S D, Hodgson W C, King R G. Effect of endothelium on diabetes-induced changes in constrictor responses mediated by 5-hydroxytryptamine in rat aorta. J Cardiouasc Pharmacol 1993; 22: 423–30
   PubMed Web of Science ®Google Scholar
• Whiting M V, Cambridge D. Canine renovascular responses to sumatriptan and 5-carboxamidotryptamine: modulation through endothelial 5-HT, -like receptors by endogenous nitric oxide. Br J Pharmacol 1995; 114: 969–74
   PubMedGoogle Scholar
• Valentin J P, Bonnafous R, John G W. Influence of the endothelium and nitric oxide on the contractile responses evoked by 5-HT1D receptor agonists in the rabbit isolated saphenous vein. Br J Pharmacol 1996; 119: 35–42
   PubMedGoogle Scholar
• Porsa E, Harper M JK, Herlihy J T. Effects of preload and eicosanoid synthesis inhibition on rat aortic smooth muscle sensitivity. Prostagland Leuk Essent Fatty Acids 1989; 38: 61–5
   PubMedGoogle Scholar
• Chester A H, Allen S P, Tadjkarimi S, Yacoub M H. Interaction between thromboxane A2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation 1993; 87: 874–80
   PubMed Web of Science ®Google Scholar
• Van Diest M, Verbeuren T J, Herman A G. Vascular interaction between 5-hydroxytryptamine and 5-lipoxygenase metabolites of arachidonic acid. Eur J Pharmacol 1993; 231: 267–74
   PubMedGoogle Scholar
• Martin G R. Vascular receptors for 5-hydroxytryptamine: distribution, function, and classification. Pharmacol Ther 1994; 62: 283–324
   PubMed Web of Science ®Google Scholar
• Yokota Y, Imaizumi Y, Asano M, Matsuda T, Watanabe M. Endothelium-derived relaxing factor released by 5-HT: distinct from nitric oxide in basilar arteries of normotensive and hypertensive rats. Br J Phamacol 1994; 113: 324–30
   PubMedGoogle Scholar
• Lamping K G. Response of native and stimulated collateral vessels to serotonin. Am J Physiol 1997; 272: H2409–15
   Google Scholar
• Laemmel E, Stiicker O, Vicaut E. Role of endothelial factors in the specific response of mouse tumour-feeding arterioles to stimulation of 5-HT, receptors. Int J Radiat Biol 1999; 75: 365–71
   PubMed Web of Science ®Google Scholar
• Zwi L J, Baguley B C, Gavin J B, Wilson W R. Blood flow failure as a major determinant in the antitumour action of flavone acetic acid (NSC 347512). J Nutl Cancer Inst 1989; 81: 1005–13
   PubMed Web of Science ®Google Scholar
• Baguley B C, Holdaway K M, Thomsem L L, Zhuang L, Zwi L J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27: 482–7
   PubMed Web of Science ®Google Scholar
• Hill S A, Lonergan S J, Denekamp J, Chaplin D J. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993; 29A: 1320–4
   PubMed Web of Science ®Google Scholar
• Hill S A, Lonergan S J, Denekamp J, Chaplin D J. The effect of vinca alkaloids on tumour blood flow. Adv Exp Med Biol 1994; 345: 417–22
   PubMedGoogle Scholar
• Baguley B C, Cole G, Thomsen L L, Zhuang L. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1993; 33: 77–81
   PubMed Web of Science ®Google Scholar
• Baguley B C, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol Res 1997; 9: 55–60
   PubMed Web of Science ®Google Scholar
• Cater D B, Petrie A, Watkinson D A. Effect of 5-hydroxytryptamine and cyproheptadine on tumour blood flow. Acta Radio1 Ther Phys Biol 1965; 3: 109–29
   PubMed Web of Science ®Google Scholar
• Jenkins D C, Wilkinson J, Lindon J C, Farrant R D, Carpenter T A, Stables J N, et al. Anti-tumour effects of 5-hydroxytryptamine (5-HT) are not entirely attributable to its effects on tumour vasculature. Int J Radiat Biol 1991; 60: 243–8
   PubMed Web of Science ®Google Scholar
• Knapp W H, Debatin J, Helus F, Sinn H -J, Ostertag H. Increased thermal response to ultrasound in the Walker carcinosarcoma treated with vasoactive drugs. Cancer Res 1989; 49: 1768–72
   PubMedGoogle Scholar
• Huhnt W, Lübbe A S. Venules and arterioles in xenotrans-planted human colon adenocarcinoma critically constrict with hyperthermia and serotonin. J Cancer Res Clin Oncol 1995; 121: 267–74
   PubMedGoogle Scholar
• Brown J M, Giaccia A J. The unique physiology of solid tumours: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408–16
   PubMed Web of Science ®Google Scholar
• Chaplin D J. Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT). Br J Cancer 1986; 54: 727–31
   PubMedGoogle Scholar
• Lash C J, Rutland M, Baguley B C, Wilson W R. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998; 78: 439–45
   PubMed Web of Science ®Google Scholar